Author

E. Voigt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Casper· 2 shared S. Reed· 2 shared A. Gerhardt· 1 shared A. Rice· 1 shared B. Morimoto· 1 shared C. A. Olson· 1 shared C. Fox· 1 shared E. Larson· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. Casper

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Heteologous saRNA-Prime, DNA Dual-Antigen-Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

A. Rice, M. Verma, E. Voigt, P. Battisti, S. Beaver, S. Reed, K. Dinkins, S. Mody, L. Zakin, S. Tanaka, B. Morimoto, W. Higashide, C. A. Olson, E. R. Gabitzsch, J. T. Safrit, , P. Soon-Shiong

This study evaluates heterologous vaccination with two SARS-CoV-2 vaccines in mice, finding enhanced humoral and T-cell responses and broad neutralizing activity against variants.

bioRxiv · Nov 29, 2021 · PreprintImmunology

A Thermostable, Flexible RNA Vaccine Delivery Platform for Pandemic Response

A. Gerhardt, E. Voigt, M. Archer, S. Reed, E. Larson, N. Van Hoeven, R. Kramer, C. Fox, C. Casper

This paper introduces a thermostable RNA vaccine delivery system stable at room temperature for 8+ months and refrigerated for 21+ months, improving vaccine distribution in low-resource settings.

bioRxiv · Feb 1, 2021Bioengineering

Sox2 is an oncogenic driver of small cell lung cancer

E. Voigt, H. Wollenzien, J. Feiner, E. Thompson, M. Vande Kamp, M. Kareta

This study investigates the role of Sox2 in Rb loss-induced small cell lung cancer to identify potential therapeutic targets.

bioRxiv · Jun 3, 2019 · PreprintCancer Biology